Inscopix showcases new brain mapping technology 

Inscopix, a brain mapping platform company developing neurotechnologies for improved disease treatments, displayed the latest product and research innovations around its miniature microscope-based neural circuitry technology at the 50th annual meeting of the Society for Neuroscience (SfN), which was held virtually November 8-11. 

Showcasing new technologies that enable dual colour imaging, neurotransmitter release and blood flow dynamics visualisations with Inscopix’s platform for understanding the circuitry of the brain, these new technologies will help researchers gain insights in neural circuit function and behavior that can ultimately lead to breakthrough discoveries and the development of novel, more precise therapeutics for neuropsychiatric, neurodegenerative diseases and brain-related injuries. Data will be shown on all three novel imaging capabilities during Inscopix’s scientific presentations. 

“We are excited to build on the commercial release earlier this year of our dual color brain imaging system, nVue. We have been amazed at how quickly nVue has been adopted by the circuit neuroscience research community, and at this SfN, we are releasing and showcasing new imaging applications enabled by nVue that take us beyond imaging of calcium activity,” said Kunal Ghosh, Founder and CEO of Inscopix. “The ability to understand neurovascular coupling by imaging blood flow dynamics together with calcium activity, and the ability to study neurotransmitter release in conjunction with neuronal calcium activity, are applications relevant to researchers across the basic and translational neuroscience spectrum.” 

“As Inscopix and its partners apply this powerful imaging approach to the development of better neurotherapeutics, these new imaging technologies allow us to gain new insights on brain circuitry, both at the neural and vascular level, and help us identify targeted therapies that are potentially both safer and more effective than currently available options,” said David Gray, CSO of Inscopix. 

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free